Johnson & Johnson Earnings

Johnson & Johnson’s revenue jumped 2.39% since last year same period to $21893Mn in the Q1 2025. On a quarterly growth basis, Johnson & Johnson has generated -2.78% fall in its revenue since last 3-months.

Johnson & Johnson’s net profit jumped 237.91% since last year same period to $10999Mn in the Q1 2025. On a quarterly growth basis, Johnson & Johnson has generated 220.58% jump in its net profits since last 3-months.

Johnson & Johnson’s net profit margin jumped 230.04% since last year same period to 50.24% in the Q1 2025. On a quarterly growth basis, Johnson & Johnson has generated 229.76% jump in its net profit margins since last 3-months.

Johnson & Johnson’s price-to-earnings ratio after this Q1 2025 earnings stands at 17.26.

Johnson & Johnson’s earning per share (EPS) estimates for the current quarter stand at 2.59 - a 28.86% jump from last quarter’s estimates.

Johnson & Johnson’s earning per share (EPS) estimates for the current year stand at 2.59.

Johnson & Johnson’s earning per share (EPS) jumped 2.21% since last year same period to 2.77 in the Q1 2025. This indicates that the Johnson & Johnson has generated 2.21% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Johnson & Johnson’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Johnson & Johnson’s return on equity (ROE) stands at 0.29.

Johnson & Johnson declared 1.24 dividend per share during the earnings announcement for Q1 2025.